Moderna (MRNA) Cash & Equivalents (2016 - 2026)

Moderna (MRNA) has 11 years of Cash & Equivalents data on file, last reported at $1.9 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.9 billion, up 17.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 17.56% YoY), and the FY2025 annual result was $2.6 billion, up 34.67% from the prior year.
• Cash & Equivalents eased to $1.9 billion in Q1 2026 per MRNA's latest filing, from $2.6 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.0 billion in Q1 2022 and troughed at $1.1 billion in Q3 2025.
• A 5-year average of $2.6 billion and a median of $2.6 billion in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents plunged 53.2% in 2022, then soared 34.67% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $3.2 billion in 2022, then fell by 9.3% to $2.9 billion in 2023, then sank by 33.71% to $1.9 billion in 2024, then soared by 34.67% to $2.6 billion in 2025, then retreated by 26.47% to $1.9 billion in 2026.
• Business Quant data shows MRNA's Cash & Equivalents at $1.9 billion in Q1 2026, $2.6 billion in Q4 2025, and $1.1 billion in Q3 2025.